Exam 5 lecture 2 Flashcards
Risk of recurrence of depression based on number of episodes
1 episode- 50-60%
2 episodes- 70%
3 episodes- 90%
What are factors that increase or decreases chances of remission
Risk becomes lower over time as duration of remission increases
Persistent mild symptoms during remission is a predictor of recurrence
Function deteriorates during episode and oes back to normal upon remission
DSM 5 Diagnostic criteria for depression
SIGE CAPS
S- sleep (insomnia/hypersomnia)
I- Interest decreased (anhedonia)
G- Guilt/worthlessness
E-ENergy loss/fatigue
C-concentration difficulties
A- Appetite change (increase or decrease)
p-Psychomotor agitation/retardation
s- suicidal ideation
Self administered rating scales for depression
PHQ-9
MDQ
goals of tx of depression
reduce or eliminate signs and symptoms of depression
restore occupational and psychosocial functioning to baseline
Reduce the risk of elapse and recurrence
reduce the risk of harmful consequences
Phases of treatment of depression
Acute- 6-12 weeks or remission (induce remission)
continuation- 4-9 months (prevent relapse)
Maintenance- indefinite treatment if > 3 major depressive disorders (prevent recurrence)
What is a boxed warning in ALL antidepressants
Boxed warning for suicidality in all antidepressants aged <24
pharmacologic classes of antidepressants
SSRIs
SNRIs
TCAs
MAOIs
What are the SSRIs
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
What are things we must remember about citalopram (side effects and metabolizers)
QTC prolongation
Substrate of 2C19and 3A4
Things to remember about fluoxetine ( half life, metabolizer)
Long half life (96-144 hrs)
2D6 inhibitor, 3A4 inhibitor
you dont have to taper
fluvoxamine metabolizer
1A2 and 2C19 inhibitor
Things to know about paroxetine
Must taper due to anticholinergic side effects
weight gain, sedation
Septal wall defect risk to the fetus
inhibitor of 2D6 and 2B6
Sertraline clinical pearls
More GI upset than other antidepressants
SNRIs adverse effects and key points
Useful in pain syndrome, muscoskeletal pain, fibromyalgia, neuropathic pain
Side effects- BP elevation and nausea
Monitoring for duloxetine
Obtain LFTs at baseline and when symptomatic or every 6 months
notable side effects of paroxetine? Fluoxetine? and SSRIs in general
weight gain (paroxetine)
Weight loss (Fluoxetine)
Generally- increased bleeding risk, hyponatremia, sexual dysfunction
What to know about desvenlafaxine? CYP metabolism?
Active metabolite of venlafaxine. Dose limiting side effect- Nausea
No major CYP interactions
What to know about duloxetine? CYP metabolism?
causes nausea
FDA warning for hepatotoxicity
inhibitor of 2D6
What to know about levomilnacipran (Metabolism)
Must adjust in renal impairement or strong 3A4 inhibitor
3A4 substrate
Things to know about venlafaxine ( metabolism)
Must be >150 mg/day to have NE effects
2D6 inhibitor at higher doses
TCAs MOA
Primarily affect serotonin and norepinephrine, but also affects dopamine
What TCA is important for exam? What is it used for?
Amitriptyline- pain and headache
TCA adverse effect
CNS sedation, reduced seizure threshold, confusion
anticholinergic, blurred vision, urinary retention, constipation
Cardiovascular, orthostatic hypotension, tachycardia
Weight gain sexual dysfunction
Key point to know about TCA
Narrow therapeutic index- fatal in OD as low as 1000 mg (4-10 tabs) due to cardiac arrhythmias or seizures
What is an important thing to know before switching antidepressant to MAO inhibitors
Must have 2 week washout period before switching antidepressants (5 week washout period if switching from fluoxetine)
What is required to do when on MAO I drug? cautions?
all require tyramine diet except for selegiline
caution due to hypotensive crisis and serotonin syndrome
tyramine diet is not required with what MAOI
Selegiline patch
Bupropion MOA? side effects?
Dopamine and norepinephrine reuptake inhibitor
Stimulated insomnia and appetite suppression
Metabolism of Bupropion
2D6 inhibitor
Contraindication of bupropion
Contraindiacted in active seizure and eating disorders